NPAF Issues Statement Regarding New FDA Label on ESAs

The National Patient Advocate Foundation recently issued a statement regarding the new Food and Drug Administration (FDA) label on erythropoietin stimulating agents (ESAs).  NPAF commends the FDA and ESA sponsors for their diligence to gather the information patients and physicians need to make well-informed decisions about the use of these important therapies.  NPAF believes that both the sponsors and the FDA have the responsibility to demonstrate to the American public that ESA drugs are safe and effective when administered within the recommended guidelines.

View Press Release

< Prev   Next >
[ Back ]
 
Advocates Network - Volunteer Advocacy Program of Services Professionals - Learn More Advocates Network - Volunteer Advocacy Program of Services Professionals - Learn More
NPAF Election Center!

Do you know where each of the Presidential candidates stands on important health care issues? Would you like to attend a candidate event and support health care access issues?  Visit the NPAF Election Center for candidate information and health care proposals.